LUM-201 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
78下垂体前葉機能低下症4

78. 下垂体前葉機能低下症


臨床試験数 : 492 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05250063
(ClinicalTrials.gov)
February 18, 202210/2/2022Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial LUM-201-01 Trial (OraGrowtH213 Trial)A Multicenter, Open-Label, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed the LUM-201-01 TrialGrowth Hormone DeficiencyDrug: LUM-201Lumos PharmaNULLEnrolling by invitation3 Years13 YearsAll20Phase 2United States;Poland
2NCT04806854
(ClinicalTrials.gov)
July 14, 202117/3/2021PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency.A Single-Center, Randomized, Open-Label, Parallel Arm Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children With Idiopathic Pediatric Growth Hormone Deficiency (PGHD).Growth Hormone DeficiencyDrug: LUM-201Lumos PharmaNULLActive, not recruiting4 Years9 YearsAll24Phase 2Chile
3EUCTR2020-000874-92-PL
(EUCTR)
22/03/202126/10/2020A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD)A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD) - LUM-201-01 Growth hormone deficiency
MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: LUM-201
INN or Proposed INN: Ibutamoren mesilate
Other descriptive name: IBUTAMOREN MESILATE
Product Name: LUM-201
INN or Proposed INN: Ibutamoren mesilate
Other descriptive name: IBUTAMOREN MESILATE
Product Name: LUM-201
INN or Proposed INN: Ibutamoren mesilate
Other descriptive name: IBUTAMOREN MESILATE
Trade Name: Norditropin
INN or Proposed INN: recombinant human growth hormone
Other descriptive name: recombinant human growth hormone
Trade Name: Norditropin
INN or Proposed INN: recombinant human growth hormone
Other descriptive name: recombinant human growth hormone
Lumos Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2United States;Poland;Ukraine;Australia;Russian Federation;Israel;New Zealand
4NCT04614337
(ClinicalTrials.gov)
December 31, 202026/10/2020Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)Growth Hormone DeficiencyDrug: LUM-201;Drug: rhGH Norditropin® pen (34 µg/kg)Lumos PharmaNULLActive, not recruiting3 Years12 YearsAll80Phase 2United States;Australia;Israel;New Zealand;Poland;Ukraine;Russian Federation